BiOptic Inc. Reports NT$0.76 EPS for 2024, Proposes NT$1.3 Dividend Per Share
2025-04-24
BiOptic Inc. (Stock Code: 6850) announced today (April 24) that its Board of Directors has approved the financial report and earnings distribution plan for fiscal year 2024. For the year 2024, BiOptic Inc. reported consolidated revenue of NT$202 million, representing an 11% year-on-year decrease. Net income attributable to the parent company was NT$22.73 million, down 40% year-on-year, with earnings per share (EPS) of NT$0.76. Despite the decline, the Board has proposed an above-average dividend payout of NT$1.3 per share, including NT$0.3 in cash dividends and NT$1 in stock dividends.
BiOptic Inc., Hermo Electric, and GGA Sign MOU to Expand Presence in Japan’s Market
2025-04-16
BiOptic Inc. (Stock Code: 6850) announced today (16th) that it has signed a Memorandum of Understanding (MOU) with Hermo Electric Co., Ltd. and GGA Corp. The three parties will combine their respective strengths to jointly expand into Japan’s biotechnology innovation and medical diagnostics markets, aiming to seize significant opportunities in the precision health sector.
BiOptic Inc. and CatchGene Co., Ltd. Complete Production Capacity Integration
2025-03-17
BiOptic Inc. (Stock Code: 6850) announced on the 12th that its subsidiary, OpenGene, has officially been merged into BiOptic Inc. The nucleic acid extraction instrument and reagent production lines previously located at the Zhonghe facility have been relocated to BiOptic’s second plant in Xindian. Going forward, the parent company will lead product development and production planning, while OpenGene will focus on market expansion to effectively integrate group resources.
2023 Summer Internship Program: BiOptic x Chang Gung Department of Biomedical Sciences
2023-09-02
Throughout this season, six interns became part of the BiOptic team, collaborating closely with our Research and Development, Marketing, and Department teams. Their growth during the internship was remarkable, and they infused our team with fresh ideas and boundless energy.
Zhejiang BiOptic has received Class I medical device certification
2023-04-27
BiOptic registered its’ second-tier subsidiary Zhejiang BiOptic on NOV 23rd, 2021, and has received Class I medical device certification. In the future, for the overall production and manufacturing capacity of BiOptic Group, it will be possible to have more diverse plans and increase productivity to effectively match the needs of the global market.
BiOptic has received ISO13485 certification from TÜV Rheinland - BiOptic
2023-02-24
BiOptic has received ISO13485 certification from TÜV Rheinland, which will be a strong asset for us to explore the international market. Relevant primary quality certification includes ISO 9001, ISO 13485, and EU CE.
